Solid Biosciences (SLDB) said Tuesday that the US Food and Drug Administration granted fast track designation to its potential treatment for Friedreich's ataxia, a degenerative disease caused by inadequate frataxin protein levels.
The company said SGT-212 will deliver the full-length frataxin gene through dual routes of administration incorporating intradentate nucleus and intravenous infusions that aim to restore therapeutic levels of the frataxin protein.
With this designation for SGT-212, Solid Biosciences said it will have more frequent interactions with the FDA and the potential to gain priority review eligibility.
The company said the planned phase 1b trial will assess the contemporaneous systemic intravenous and bilateral intradentate nucleus administration of SGT-212, with dosing expected to start in H2 and participants to be followed for five years after receiving the treatment.
The company's shares were down nearly 3% in recent trading.
Price: 3.18, Change: -0.09, Percent Change: -2.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.